Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC.

Moroney LB, Ward EC, Helios J, Crombie J, Burns CL, Blake C, Comans T, Chua B, Kenny L, Hughes BGM.

Support Care Cancer. 2019 Jul 27. doi: 10.1007/s00520-019-04992-x. [Epub ahead of print]

PMID:
31352509
2.

The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer.

Turner J, Yates P, Kenny L, Gordon LG, Burmeister B, Hughes BGM, McCarthy AL, Perry C, Chan RJ, Paviour A, Skerman H, Batstone M, Mackenzie L.

Support Care Cancer. 2019 Apr 2. doi: 10.1007/s00520-019-04748-7. [Epub ahead of print]

PMID:
30941580
3.

Patterns of care for stage III non-small cell lung cancer in Australia.

Parente P, Chan BA, Hughes BGM, Jasas K, Joshi R, Kao S, Hegi-Johnson F, Hui R, McLaughlin-Barrett S, Nordman I, Stone E.

Asia Pac J Clin Oncol. 2019 Jun;15(3):93-100. doi: 10.1111/ajco.13140. Epub 2019 Mar 14. Review.

PMID:
30868747
4.

Doxorubicin induces de novo expression of N-terminal-truncated matrix metalloproteinase-2 in cardiac myocytes.

Chan BYH, Roczkowsky A, Moser N, Poirier M, Hughes BG, Ilarraza R, Schulz R.

Can J Physiol Pharmacol. 2018 Dec;96(12):1238-1245. doi: 10.1139/cjpp-2018-0275. Epub 2018 Oct 11.

PMID:
30308129
5.

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.

Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, John T.

J Thorac Oncol. 2018 Nov;13(11):1784-1791. doi: 10.1016/j.jtho.2018.08.007. Epub 2018 Aug 22.

PMID:
30142389
6.

Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns.

Moroney LB, Helios J, Ward EC, Crombie J, Burns CL, Yeo SQ, Pelecanos A, Spurgin AL, Blake C, Kenny L, Chua B, Hughes BGM.

Support Care Cancer. 2019 Feb;27(2):573-581. doi: 10.1007/s00520-018-4352-5. Epub 2018 Jul 17.

PMID:
30019149
7.

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.

8.

Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns.

Moroney LB, Helios J, Ward EC, Crombie J, Pelecanos A, Burns CL, Spurgin AL, Blake C, Kenny L, Chua B, Hughes BGM.

Head Neck. 2018 Sep;40(9):1955-1966. doi: 10.1002/hed.25182. Epub 2018 May 13.

PMID:
29756244
9.

Estimating the occurrence of primary ubiquinone deficiency by analysis of large-scale sequencing data.

Hughes BG, Harrison PM, Hekimi S.

Sci Rep. 2017 Dec 18;7(1):17744. doi: 10.1038/s41598-017-17564-y.

10.

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

McKeage MJ, Kotasek D, Markman B, Hidalgo M, Millward MJ, Jameson MB, Harris DL, Stagg RJ, Kapoun AM, Xu L, Hughes BGM.

Target Oncol. 2018 Feb;13(1):89-98. doi: 10.1007/s11523-017-0543-0.

PMID:
29188408
11.

Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer.

Brown T, Banks M, Hughes BGM, Lin C, Kenny LM, Bauer JD.

Oral Oncol. 2017 Sep;72:17-25. doi: 10.1016/j.oraloncology.2017.06.025. Epub 2017 Jul 5.

PMID:
28797454
12.

Tube feeding during treatment for head and neck cancer - Adherence and patient reported barriers.

Brown T, Banks M, Hughes BGM, Lin C, Kenny L, Bauer J.

Oral Oncol. 2017 Sep;72:140-149. doi: 10.1016/j.oraloncology.2017.07.017. Epub 2017 Jul 25.

PMID:
28797450
13.

Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.

Roberts K, Culleton V, Lwin Z, O'Byrne K, Hughes BG.

Asia Pac J Clin Oncol. 2017 Aug;13(4):277-288. doi: 10.1111/ajco.12698. Epub 2017 Jul 12. Review.

PMID:
28699304
14.

Many possible maximum lifespan trajectories.

Hughes BG, Hekimi S.

Nature. 2017 Jun 28;546(7660):E8-E9. doi: 10.1038/nature22786. No abstract available.

PMID:
28658230
15.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S.

Eur J Cancer. 2017 Sep;82:27-33. doi: 10.1016/j.ejca.2017.05.019. Epub 2017 Jul 10.

PMID:
28646771
16.

Randomised controlled trial of early prophylactic feeding vs standard care in patients with head and neck cancer.

Brown TE, Banks MD, Hughes BGM, Lin CY, Kenny LM, Bauer JD.

Br J Cancer. 2017 Jun 27;117(1):15-24. doi: 10.1038/bjc.2017.138. Epub 2017 May 23.

17.

Investigation of p16 status, chemotherapy regimen, and other nutrition markers for predicting gastrostomy in patients with head and neck cancer.

Brown TE, Wittholz K, Way M, Banks MD, Hughes BG, Lin CY, Kenny LM, Bauer JD.

Head Neck. 2017 May;39(5):868-875. doi: 10.1002/hed.24630. Epub 2017 Feb 23.

PMID:
28230929
18.

Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study.

Hughes BG, Ahern E, Lehman M, Pratt G, Dauth M, Pritchard W, Wockner L, Horwood K.

Asia Pac J Clin Oncol. 2017 Jun;13(3):137-144. doi: 10.1111/ajco.12649. Epub 2017 Feb 9.

PMID:
28181415
19.

Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin.

Nottage MK, Lin C, Hughes BG, Kenny L, Smith DD, Houston K, Francesconi A.

Head Neck. 2017 Apr;39(4):679-683. doi: 10.1002/hed.24662. Epub 2016 Dec 29.

PMID:
28032670
20.

Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT±concurrent chemotherapy.

Moroney LB, Helios J, Ward EC, Crombie J, Wockner LF, Burns CL, Spurgin AL, Blake C, Kenny L, Hughes BG.

Oral Oncol. 2017 Jan;64:1-8. doi: 10.1016/j.oraloncology.2016.11.009. Epub 2016 Nov 25.

PMID:
28024718
21.

Comparison of Nutritional and Clinical Outcomes in Patients with Head and Neck Cancer Undergoing Chemoradiotherapy Utilizing Prophylactic versus Reactive Nutrition Support Approaches.

Brown TE, Banks MD, Hughes BGM, Lin CY, Kenny LM, Bauer JD.

J Acad Nutr Diet. 2018 Apr;118(4):627-636. doi: 10.1016/j.jand.2016.10.013. Epub 2016 Dec 13.

PMID:
27986517
22.

Different Mechanisms of Longevity in Long-Lived Mouse and Caenorhabditis elegans Mutants Revealed by Statistical Analysis of Mortality Rates.

Hughes BG, Hekimi S.

Genetics. 2016 Nov;204(3):905-920. doi: 10.1534/genetics.116.192369. Epub 2016 Sep 16.

23.

Matrix metalloproteinase-2 in oncostatin M-induced sarcomere degeneration in cardiomyocytes.

Fan X, Hughes BG, Ali MA, Chan BY, Launier K, Schulz R.

Am J Physiol Heart Circ Physiol. 2016 Jul 1;311(1):H183-9. doi: 10.1152/ajpheart.00229.2016. Epub 2016 May 6.

24.

Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart.

Baghirova S, Hughes BG, Poirier M, Kondo MY, Schulz R.

J Mol Cell Cardiol. 2016 May;94:153-161. doi: 10.1016/j.yjmcc.2016.04.004. Epub 2016 Apr 11.

PMID:
27079252
25.

Validation of an updated evidence-based protocol for proactive gastrostomy tube insertion in patients with head and neck cancer.

Brown TE, Getliffe V, Banks MD, Hughes BG, Lin CY, Kenny LM, Bauer JD.

Eur J Clin Nutr. 2016 May;70(5):574-81. doi: 10.1038/ejcn.2015.230. Epub 2016 Feb 10.

PMID:
26862007
26.

Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells.

Baghirova S, Hughes BG, Hendzel MJ, Schulz R.

MethodsX. 2015 Nov 7;2:440-5. doi: 10.1016/j.mex.2015.11.001. eCollection 2015.

27.

A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial.

Davidson A, Veillard AS, Tognela A, Chan MM, Hughes BG, Boyer M, Briscoe K, Begbie S, Abdi E, Crombie C, Long J, Boyce A, Lewis CR, Varma S, Broad A, Muljadi N, Chinchen S, Espinoza D, Coskinas X, Pavlakis N, Millward M, Stockler MR; Australasian Lung cancer Trials Group (ALTG); Australasian Lung cancer Trials Group ALTG.

Ann Oncol. 2015 Nov;26(11):2280-6. doi: 10.1093/annonc/mdv373. Epub 2015 Sep 7.

PMID:
26347110
28.

New radiotherapy techniques do not reduce the need for nutrition intervention in patients with head and neck cancer.

Brown T, Banks M, Hughes BG, Lin C, Kenny LM, Bauer JD.

Eur J Clin Nutr. 2015 Oct;69(10):1119-24. doi: 10.1038/ejcn.2015.141. Epub 2015 Aug 26.

PMID:
26306565
29.

Improving guideline sensitivity and specificity for the identification of proactive gastrostomy placement in patients with head and neck cancer.

Brown TE, Crombie J, Spurgin AL, Tripcony L, Keller J, Hughes BG, Dickie G, Kenny LM, Hodge RA.

Head Neck. 2016 Apr;38 Suppl 1:E1163-71. doi: 10.1002/hed.24184. Epub 2015 Aug 13.

PMID:
26268152
30.

Dynamic Alterations to α-Actinin Accompanying Sarcomere Disassembly and Reassembly during Cardiomyocyte Mitosis.

Fan X, Hughes BG, Ali MA, Cho WJ, Lopez W, Schulz R.

PLoS One. 2015 Jun 15;10(6):e0129176. doi: 10.1371/journal.pone.0129176. eCollection 2015.

31.

Swallowing outcomes and PEG dependence in head and neck cancer patients receiving definitive or adjuvant radiotherapy +/- chemotherapy with a proactive PEG: a prospective study with long term follow up.

Crombie JM, Ng S, Spurgin AL, Ward EC, Brown TE, Hughes BG.

Oral Oncol. 2015 Jun;51(6):622-8. doi: 10.1016/j.oraloncology.2015.03.006. Epub 2015 Apr 10.

PMID:
25865554
32.

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.

Chan BA, Hughes BG.

Transl Lung Cancer Res. 2015 Feb;4(1):36-54. doi: 10.3978/j.issn.2218-6751.2014.05.01. Review.

33.

Compensatory elevation of voluntary activity in mouse mutants with impaired mitochondrial energy metabolism.

Lapointe J, Hughes BG, Bigras E, Hekimi S.

Physiol Rep. 2014 Nov 20;2(11). pii: e12214. doi: 10.14814/phy2.12214. Print 2014 Nov 1.

34.

Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma.

Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, Zarate D, Simpson F, Porceddu SV.

Ann Oncol. 2014 Oct;25(10):2047-52. doi: 10.1093/annonc/mdu368. Epub 2014 Aug 4.

PMID:
25091317
35.

Targeting MMP-2 to treat ischemic heart injury.

Hughes BG, Schulz R.

Basic Res Cardiol. 2014 Jul;109(4):424. doi: 10.1007/s00395-014-0424-y. Epub 2014 Jul 2. Review.

PMID:
24986221
36.

Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma.

Hansen AR, Hughes BG, Paul S, Steadman P, Sommerville S, Dickinson IC, Walpole ET, Thomson DB, Mar Fan HG, Joubert WL.

Asia Pac J Clin Oncol. 2016 Jun;12(2):e222-8. doi: 10.1111/ajco.12167. Epub 2014 Feb 20.

PMID:
24571381
37.

MMP-2 is localized to the mitochondria-associated membrane of the heart.

Hughes BG, Fan X, Cho WJ, Schulz R.

Am J Physiol Heart Circ Physiol. 2014 Mar 1;306(5):H764-70. doi: 10.1152/ajpheart.00909.2013. Epub 2013 Dec 27.

38.

Validated swallowing and nutrition guidelines for patients with head and neck cancer: identification of high-risk patients for proactive gastrostomy.

Brown TE, Spurgin AL, Ross L, Tripcony L, Keller J, Hughes BG, Hodge R, Walker Q, Banks M, Kenny LM, Crombie J.

Head Neck. 2013 Oct;35(10):1385-91. doi: 10.1002/hed.23146. Epub 2012 Sep 13.

PMID:
22972623
39.

Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution.

Hughes BG, Jain VK, Brown T, Spurgin AL, Hartnett G, Keller J, Tripcony L, Appleyard M, Hodge R.

Head Neck. 2013 Mar;35(3):436-42. doi: 10.1002/hed.22992. Epub 2012 May 18.

PMID:
22605643
40.

Quality-of-life among head and neck cancer survivors at one year after treatment--a systematic review.

So WK, Chan RJ, Chan DN, Hughes BG, Chair SY, Choi KC, Chan CW.

Eur J Cancer. 2012 Oct;48(15):2391-408. doi: 10.1016/j.ejca.2012.04.005. Epub 2012 May 12. Review.

PMID:
22579456
41.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR.

Clin Cancer Res. 2012 Apr 15;18(8):2391-401. doi: 10.1158/1078-0432.CCR-11-3148. Epub 2012 Apr 5.

42.

Challenging the distal-to-proximal cannulation technique for administration of anticancer therapies: a prospective cohort study.

Chan RJ, Alexander A, Bransdon M, Webster J, Hughes BG, Brown L, Graham T.

Cancer Nurs. 2012 Sep-Oct;35(5):E35-40.

PMID:
22067699
43.

A mild impairment of mitochondrial electron transport has sex-specific effects on lifespan and aging in mice.

Hughes BG, Hekimi S.

PLoS One. 2011;6(10):e26116. doi: 10.1371/journal.pone.0026116. Epub 2011 Oct 10.

44.

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.

Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM.

Clin Cancer Res. 2011 May 15;17(10):3304-15. doi: 10.1158/1078-0432.CCR-10-2763. Epub 2011 Mar 1.

45.

Clinicopathological report: bilateral choroidal metastases from papillary thyroid cancer.

Tran K, Bigby KJ, Hughes BG, Lee L, Allison R.

Asia Pac J Clin Oncol. 2011 Mar;7(1):11-4. doi: 10.1111/j.1743-7563.2010.01332.x. Epub 2010 Nov 3.

PMID:
21332645
46.

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme.

Francesconi AB, Dupre S, Matos M, Martin D, Hughes BG, Wyld DK, Lickliter JD.

J Clin Neurosci. 2010 Aug;17(8):970-4. doi: 10.1016/j.jocn.2009.12.009. Epub 2010 Jun 11.

PMID:
20541421
47.

Mclk1+/- mice are not resistant to the development of atherosclerosis.

Hughes BG, Hekimi S.

Lipids Health Dis. 2009 May 5;8:16. doi: 10.1186/1476-511X-8-16.

48.

The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT.

Lee JC, Hartnett GF, Hughes BG, Ravi Kumar AS.

Nucl Med Commun. 2009 May;30(5):333-7. doi: 10.1097/MNM.0b013e32832999fa.

PMID:
19262416
49.

Sex differences in left ventricular function and beta-receptor responsiveness following prolonged strenuous exercise.

Scott JM, Esch BT, Haykowsky MJ, Isserow S, Koehle MS, Hughes BG, Zbogar D, Bredin SS, McKenzie DC, Warburton DE.

J Appl Physiol (1985). 2007 Feb;102(2):681-7. Epub 2006 Nov 2.

50.

Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C.

Bromley J, Hughes BG, Leong DC, Buckley NA.

Ann Pharmacother. 2005 Sep;39(9):1566-9. Epub 2005 Jul 12.

PMID:
16014371

Supplemental Content

Loading ...
Support Center